- Butterfly Network’s chip-based handheld ultrasound costs ~$4,000 vs. $30,000-$200,000 for traditional systems, with 150,000+ devices deployed globally across hospitals, rural clinics, and conflict zones.
- A single semiconductor chip with 9,000 sensors replaces the multiple acoustic lenses of traditional machines, enabling heart, fetal, and procedural imaging from one smartphone-connected probe.
- Butterfly recently got FDA clearance for an AI gestational age estimation tool and signed a $25M co-development deal with Midjourney to build generative AI imaging features.
- Two-thirds of the world has no access to medical imaging — Butterfly was founded to close that gap, including eventually enabling home-based ultrasound.
What Happened?
Butterfly Network is pushing ahead with its mission to make ultrasound accessible to anyone, anywhere. Its iQ3 device uses a proprietary chip with 9,000 tiny sensors that vibrate at different frequencies, replacing the multiple acoustic lenses required by traditional cart-based systems. The probe plugs into a smartphone and retails for about $4,000, compared to $30,000-$200,000 for conventional machines. More than 150,000 devices have been distributed globally — to hospital systems, rural clinics in Africa, military medics in Ukraine, and even the International Space Station. The company recently received FDA clearance for an AI tool to estimate gestational age from a simple scan, moving toward enabling non-specialist users to perform meaningful diagnostic imaging.
Why It Matters?
Two-thirds of the world has no access to medical imaging — a gap that drives enormous preventable disease burden, particularly in obstetrics, cardiac care, and emergency medicine. CEO Joe DeVivo frames the problem personally: his own son needed a three-hour ER wait for an ultrasound that would have been unnecessary had his pediatrician owned the device. Butterfly’s AI-guided imaging is designed to collapse the barrier between trained sonographers and anyone who picks up the probe. The company’s $15 million co-development deal with generative AI firm Midjourney — plus a $10 million annual licensing fee — reflects a bet that AI can guide probe placement and interpret results in real time, democratizing a tool that has historically required years of training to use effectively.
What’s Next?
Butterfly is targeting primary care physicians, paramedics, and eventually patients themselves through AI applications that automate image guidance and interpretation. The company is also exploring new form factors enabled by its chip architecture, including adhesive patches and endoscope-integrated devices. Financially, Butterfly posted $97.6 million in revenue and a $77.1 million net loss in 2025, with a market cap of about $1.37 billion — down roughly 50% from its 2021 SPAC listing. The path to profitability runs through AI-driven software subscriptions and third-party diagnostic application partnerships, as the hardware becomes a platform for an expanding ecosystem of clinical tools.
Source: Healthcare Dive
